Genelux Corporation (GNLX)
NASDAQ: GNLX · Real-Time Price · USD
3.080
+0.050 (1.65%)
At close: Mar 28, 2025, 4:00 PM
3.230
+0.150 (4.87%)
After-hours: Mar 28, 2025, 6:14 PM EDT
Genelux Employees
Genelux had 23 employees as of December 31, 2023. The number of employees increased by 8 or 53.33% compared to the previous year.
Employees
23
Change (1Y)
8
Growth (1Y)
53.33%
Revenue / Employee
$348
Profits / Employee
-$1,298,652
Market Cap
114.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 23 | 8 | 53.33% |
| Dec 31, 2022 | 15 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GNLX News
- 2 days ago - Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 days ago - Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Genelux Corporation Announces New Chief Financial Officer - GlobeNewsWire
- 3 months ago - Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - GlobeNewsWire
- 5 months ago - Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference - GlobeNewsWire
- 5 months ago - Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point - Seeking Alpha
- 5 months ago - Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer - GlobeNewsWire
- 6 months ago - Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire